Plain-English translation of NCT03862677 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are collecting tumor tissue, fluid from the abdomen, and blood samples from people with ovarian cancer to look for immune markers—special signals in the body that might predict how well treatment will work. By studying these markers in people receiving surgery, chemotherapy, or immunotherapy, researchers hope to better understand which patients are most likely to benefit from each type of treatment.
Currently, doctors don't have good ways to predict which ovarian cancer patients will respond well to different treatments. By identifying these immune markers early, doctors may one day be able to personalize treatment plans and help more patients achieve better outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will collect tissue samples during surgery, fluid from your abdomen if available, and blood samples to study your immune markers. These samples will be taken as part of your standard cancer care—during surgery and routine appointments—so you won't need extra visits just for this study. Your samples will be analyzed to help researchers understand which immune markers predict treatment success.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Netherlands
Sponsor
Leiden University Medical Center
Enrollment target
~300 participants
Started
August 2020
Primary completion
January 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Judith R Kroep, MD PhD
Leiden University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.